Lifetech KONAR MFO Post-Market Clinical Follow-Up Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-04

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to collect real-world data on patient outcomes and evaluate the procedural success and performance of the Lifetech KONAR-MF™ VSD Occluder for patients with ventricular septal defect (VSD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

NCT04034498

Perimembranous Ventricular Septal Defect

ACTIVE_NOT_RECRUITING

Mitroflow DL Post Approval Study- North America

NCT02351726

Aortic Stenosis Aortic Regurgitation Aortic Valve Insufficiency +6 more

TERMINATED NA

Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System

NCT00968032

Foramen Ovale, Patent Heart Catheterization Heart Septal Defects, Atrial

COMPLETED NA

Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device.

NCT04382612

Mitral Regurgitation

TERMINATED NA

Beating Heart Mitral Valve Repair With the HARPOON™ System

NCT04375332

Mitral Regurgitation

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized prospective post-marketing clinical follow-up study (PMCFS) in order to evaluate the feasibility and safety of the Lifetech KONAR-MF™ VSD Occluder device used for patients with ventricular septal defect. The implantation should be performed in accordance with the instructions for use (IFU).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventricular Septal Defect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ventricular septal defect

All patients who signed informed consent and are implanted with a KONAR-MF™ VSD Occluder device will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:

* Before discharge
* 1-3 months after the Procedure
* 6 months after the procedure
* 12 months after the procedure

KONAR-MF™ VSD Occluder

Intervention Type DEVICE

All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KONAR-MF™ VSD Occluder

All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients have a clinically relevant ventricular septum defect (VSD) by Echocardiography and/or X-ray examination according to current clinical standards and center-specific protocols.
2. The patient should be older than 6 months of age and a bodyweight heavier than 8kg.
3. Defect diameter (by 2D Echocardiography): The size of the VSD is larger than or equal to 2mm and less than 10mm.
4. Upper margin of VSD to aortic valve distance \>2 mm for models 6-4, 8-6, 10-8, 12-10, 14-12 and \>2.5mm for models 5-3, 7-5, 9-7, in case of PmVSD.
5. Only left to right shunt of the ventricular shunt.

Exclusion Criteria

1. Any contraindication mentioned in the corresponding IFU\*.

* Note: In IFU, contraindications for The KONAR-MFTM VSD Occluder are as follows:

1. Patient has extensive congenital cardinal anomaly which can only be adequately repaired by cardiac surgery.
2. Presence of thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the defect is gained.
3. Active endocarditis or other infections-producing bacteria.
4. The implant of KONAR-MFTM VSD Occluder would cause an obvious interference with the aortic valve or the atrioventricular valve.
5. Patients with severely increased pulmonary vascular resistance and a right-to-left shunt and patients with documented irreversible pulmonary vascular disease.
6. Patients with contraindications to anti-platelet therapy or agents.
2. The patient does present with an aortic valve prolapsing into the VSD.
3. Currently participating in other investigational drugs- or device studies.
4. The patient who is pregnant, planning to become pregnant, or breastfeeding.
5. Patients don't give informed written consent for the procedure.
6. Patient with other cardiac anomalies by surgery therapy.

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No